4187 related articles for article (PubMed ID: 15721407)
1. Lymph-vascular space invasion and number of positive para-aortic node groups predict survival in node-positive patients with endometrial cancer.
Watari H; Todo Y; Takeda M; Ebina Y; Yamamoto R; Sakuragi N
Gynecol Oncol; 2005 Mar; 96(3):651-7. PubMed ID: 15721407
[TBL] [Abstract][Full Text] [Related]
2. Para-aortic lymphadenectomy may improve disease-related survival in patients with multipositive pelvic lymph node stage IIIc endometrial cancer.
Fujimoto T; Nanjyo H; Nakamura A; Yokoyama Y; Takano T; Shoji T; Nakahara K; Yamada H; Mizunuma H; Yaegashi N; Sugiyama T; Kurachi H; Sato A; Tanaka T
Gynecol Oncol; 2007 Nov; 107(2):253-9. PubMed ID: 17640720
[TBL] [Abstract][Full Text] [Related]
3. FIGO stage IIIC endometrial carcinoma with metastases confined to pelvic lymph nodes: analysis of treatment outcomes, prognostic variables, and failure patterns following adjuvant radiation therapy.
Nelson G; Randall M; Sutton G; Moore D; Hurteau J; Look K
Gynecol Oncol; 1999 Nov; 75(2):211-4. PubMed ID: 10525373
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of postoperative chemotherapy for para-aortic lymph node metastasis of endometrial cancer.
Takeshima N; Umayahara K; Fujiwara K; Hirai Y; Takizawa K; Hasumi K
Gynecol Oncol; 2006 Aug; 102(2):214-7. PubMed ID: 16457876
[TBL] [Abstract][Full Text] [Related]
5. Analysis of FIGO Stage IIIc endometrial cancer patients.
McMeekin DS; Lashbrook D; Gold M; Johnson G; Walker JL; Mannel R
Gynecol Oncol; 2001 May; 81(2):273-8. PubMed ID: 11330962
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant chemotherapy as treatment of high-risk stage I and II endometrial cancer.
Aoki Y; Watanabe M; Amikura T; Obata H; Sekine M; Yahata T; Fujita K; Tanaka K
Gynecol Oncol; 2004 Aug; 94(2):333-9. PubMed ID: 15297170
[TBL] [Abstract][Full Text] [Related]
7. [Survival, prognostic factors and modern tendencies in adjuvant treatment of diagnosed endometrial cancer patients with or without lymph node dissection].
Ivanov I
Akush Ginekol (Sofiia); 2009; 48 Suppl 1():3-11. PubMed ID: 20387272
[TBL] [Abstract][Full Text] [Related]
8. The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer.
Alvarez Secord A; Havrilesky LJ; Bae-Jump V; Chin J; Calingaert B; Bland A; Rutledge TL; Berchuck A; Clarke-Pearson DL; Gehrig PA
Gynecol Oncol; 2007 Nov; 107(2):285-91. PubMed ID: 17688923
[TBL] [Abstract][Full Text] [Related]
9. Long-term survival in patients with para-aortic lymph node metastasis with systematic retroperitoneal lymphadenectomy followed by adjuvant chemotherapy in endometrial carcinoma.
Hiura M; Nogawa T; Matsumoto T; Yokoyama T; Shiroyama Y; Wroblewski J
Int J Gynecol Cancer; 2010 Aug; 20(6):1000-5. PubMed ID: 20683408
[TBL] [Abstract][Full Text] [Related]
10. Para-aortic lymphadenectomy improves survival in patients with intermediate to high-risk endometrial carcinoma.
Chang SJ; Kim WY; Yoon JH; Yoo SC; Chang KH; Ryu HS
Acta Obstet Gynecol Scand; 2008; 87(12):1361-9. PubMed ID: 18951214
[TBL] [Abstract][Full Text] [Related]
11. Clusterin expression predicts survival of invasive cervical cancer patients treated with radical hysterectomy and systematic lymphadenectomy.
Watari H; Ohta Y; Hassan MK; Xiong Y; Tanaka S; Sakuragi N
Gynecol Oncol; 2008 Mar; 108(3):527-32. PubMed ID: 18177691
[TBL] [Abstract][Full Text] [Related]
12. Stage III endometrial cancer: analysis of prognostic factors and failure patterns after adjuvant chemotherapy.
Aoki Y; Kase H; Watanabe M; Sato T; Kurata H; Tanaka K
Gynecol Oncol; 2001 Oct; 83(1):1-5. PubMed ID: 11585406
[TBL] [Abstract][Full Text] [Related]
13. Lymphvascular space involvement: an independent prognostic factor in endometrial cancer.
Briët JM; Hollema H; Reesink N; Aalders JG; Mourits MJ; ten Hoor KA; Pras E; Boezen HM; van der Zee AG; Nijman HW
Gynecol Oncol; 2005 Mar; 96(3):799-804. PubMed ID: 15721428
[TBL] [Abstract][Full Text] [Related]
14. The impact of age on long-term outcome in patients with endometrial cancer treated with postoperative radiation.
Jolly S; Vargas CE; Kumar T; Weiner SA; Brabbins DS; Chen PY; Floyd W; Martinez AA
Gynecol Oncol; 2006 Oct; 103(1):87-93. PubMed ID: 16545441
[TBL] [Abstract][Full Text] [Related]
15. [Multivariate analysis of prognostic factors in endometrial carcinoma].
Li B; Wu LY; Li SM; Zhang WH; Zhang R; Ma SK
Ai Zheng; 2004 Sep; 23(9):1085-8. PubMed ID: 15363208
[TBL] [Abstract][Full Text] [Related]
16. Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology.
Lutman CV; Havrilesky LJ; Cragun JM; Secord AA; Calingaert B; Berchuck A; Clarke-Pearson DL; Soper JT
Gynecol Oncol; 2006 Jul; 102(1):92-7. PubMed ID: 16406063
[TBL] [Abstract][Full Text] [Related]
17. FIGO stage IIIC endometrial carcinoma: prognostic factors and outcomes.
Hoekstra AV; Kim RJ; Small W; Rademaker AW; Helenowski IB; Singh DK; Schink JC; Lurain JR
Gynecol Oncol; 2009 Aug; 114(2):273-8. PubMed ID: 19428094
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of lymph node metastasis and clear cell histology in ovarian carcinoma limited to the pelvis (pT1M0 and pT2M0).
Sakuragi N; Yamada H; Oikawa M; Okuyama K; Fujino T; Sagawa T; Fujimoto S
Gynecol Oncol; 2000 Nov; 79(2):251-5. PubMed ID: 11063653
[TBL] [Abstract][Full Text] [Related]
19. Indispensability of pelvic and paraaortic lymphadenectomy in endometrial cancers.
Yokoyama Y; Maruyama H; Sato S; Saito Y
Gynecol Oncol; 1997 Mar; 64(3):411-7. PubMed ID: 9062142
[TBL] [Abstract][Full Text] [Related]
20. Endometrioid uterine cancer: histopathological risk factors of local and distant recurrence.
Fujimoto T; Nanjyo H; Fukuda J; Nakamura A; Mizunuma H; Yaegashi N; Sugiyama T; Kurachi H; Sato A; Tanaka T
Gynecol Oncol; 2009 Feb; 112(2):342-7. PubMed ID: 19062082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
